Potassium Chloride Recall: What You Need to Know about the FDA’s Action and How to Keep Yourself Safe
Last week, the US Food and Drug Administration (FDA) announced a voluntary recall of 135 batches of capsules due to flawed medication that could potentially cause cardiac arrest. The recall included 114 batches of potassium chloride extended-release capsules manufactured by Glenmark Pharmaceuticals and 21 batches of the same capsules produced by BluePoint Laboratories, on behalf of American Health Packaging.
The recall was issued because of failed dissolution testing, which could result in high potassium levels, also known as hyperkalemia. Hyperkalemia is a condition where there is too much potassium in the blood and can lead to an irregular heartbeat that could result in cardiac arrest.
According to the FDA, the recalls took place last week, with no reports of hyperkalemia or serious adverse events related to the recall so far. The potassium chloride extended-release capsules are intended for patients with low potassium levels, or hypokalemia, and are available in bottles of 100 and 500. The FDA has listed the recalled batch numbers for both Glenmark and BluePoint capsules on their website.
Consumers who have these capsules should consult with their physician or healthcare provider before stopping their use and seek medical advice if they have experienced any issues related to the drug product. The FDA advises consumers not to take any dosage unless it has been prescribed by a licensed healthcare professional.
